1. |
Beydoun A, D'Souza J, Hebert D, et al. Lacosamide:pharmacology, mechanisms of action and pooled efficacy and safety data in partial-onset seizures. Expert Rev Neurother, 2009, 9(1):33-42.
|
2. |
Ben-Menachem E, Biton V, Jatuzis D, et al. Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia, 2007,48(7):1308-1317.
|
3. |
Halasz P, Kalviainen R, Mazurkiewicz-Beldzinska M, et al. Adjunctive lacosamide for partial-onset seizures:Efficacy and safety results from a randomized controlled trial. Epilepsia, 2009, 50(3):443-453.
|
4. |
Chung S, Sperling MR, Biton V, et al. Lacosamide as adjunctive therapy for partial-onset seizures:a randomized controlled trial. Epilepsia, 2010, 51(6):958-967.
|
5. |
Sawh SC, Newman JJ, Deshpande S, et al. Lacosamide adjunctive therapy for partial-onset seizures:a meta-analysis. PeerJ, 2013,1:e114.
|
6. |
Grosso S, Parisi P, Spalice A, et al. Efficacy and safety of lacosamide in infants and young children with refractory focal epilepsy. Eur J Paediatr Neurol, 2014, 18(1):55-59.
|
7. |
Pasha I, Kamate M, Didagi SK. Efficacy and tolerability of lacosamide as an adjunctive therapy in children with refractory partial epilepsy. Pediatr Neurol, 2014, 51(4):509-514.
|
8. |
Gulati P, Cannell P, Ghia T, et al. Lacosamide as adjunctive therapy in treatment-resistant epilepsy in childhood. J Paediatr Child Health, 2015.
|
9. |
Paquette V, Culley C, Greanya ED, et al. Lacosamide as adjunctive therapy in refractory epilepsy in adults:a systematic review. Seizure, 2015, 25(2):1-17.
|
10. |
de Biase S, Gigli GL, Valente M, et al. Lacosamide for the treatment of epilepsy. Expert Opin Drug Metab Toxicol, 2014, 10(3):459-468.
|
11. |
Santamarina E, Toledo M, Sueiras M, et al. Usefulness of intravenous lacosamide in status epilepticus. J Neurol, 2013, 260(12):3122-3128.
|
12. |
Kellinghaus C, Berning S, Stogbauer F. Intravenous lacosamide or phenytoin for treatment of refractory status epilepticus. Acta Neurol Scand, 2014, 129(5):294-299.
|
13. |
Grosso S, Zamponi N, Bartocci A, et al. Lacosamide in children with refractory status epilepticus. A multicenter Italian experience. Eur J Paediatr Neurol, 2014, 18(5):604-608.
|
14. |
d'Orsi G, Pacillo F, Trivisano M, et al. Lacosamide in absence status epilepticus. Seizure, 2014, 23(5):397-398.
|
15. |
Sutter R, Marsch S, Ruegg S. Safety and efficacy of intravenous lacosamide for adjunctive treatment of refractory status epilepticus:a comparative cohort study. CNS Drugs, 2013, 27(4):321-329.
|
16. |
Legros B, Depondt C, Levy-Nogueira M, et al. Intravenous lacosamide in refractory seizure clusters and status epilepticus:comparison of 200 and 400 mg loading doses. Neurocrit Care, 2014, 20(3):484-488.
|
17. |
Miro J, Toledo M, Santamarina E, et al. Efficacy of intravenous lacosamide as an add-on treatment in refractory status epilepticus:a multicentric prospective study. Seizure, 2013, 22(1):77-79.
|
18. |
Novy J, Bartolini E, Bell GS, et al. Long-term retention of lacosamide in a large cohort of people with medically refractory epilepsy:a single centre evaluation. Epilepsy Res, 2013, 106(1-2):250-256.
|
19. |
Verrotti A, Loiacono G, Olivieri C, et al. Lacosamide in patients with pharmacoresistant epilepsy. Expert Opin Pharmacother, 2012, 13(14):2065-2072.
|
20. |
Villanueva V, Lopez-Gomariz E, Lopez-Trigo J, et al. Rational polytherapy with lacosamide in clinical practice:results of a Spanish cohort analysis RELACOVA. Epilepsy Behav, 2012, 23(3):298-304.
|
21. |
Husain A, Chung S, Faught E, et al. Long-term safety and efficacy in patients with uncontrolled partial-onset seizures treated with adjunctive lacosamide:results from a Phase Ⅲ open-label extension trial. Epilepsia, 2012, 53(3):521-528.
|
22. |
Stephen LJ, Kelly K, Parker P, et al. Adjunctive lacosamide in clinical practice:sodium blockade with a difference? Epilepsy Behav, 2011, 22(3):499-504.
|
23. |
Flores L, Kemp S, Colbeck K, et al. Clinical experience with oral lacosamide as adjunctive therapy in adult patients with uncontrolled epilepsy:a multicentre study in epilepsy clinics in the United Kingdom (UK). Seizure, 2012, 21(7):512-517.
|
24. |
Harden CL, Cohn A, Lowe M, et al. Initial post marketing experience with lacosamide in adult patients with epilepsy. Epilepsy Res, 2012, 98(2-3):260-263.
|
25. |
Kamel JT, DeGruyter MA, D'Souza WJ, et al. Clinical experience with using lacosamide for the treatment of epilepsy in a tertiary centre. Acta Neurol Scand, 2013, 127(3):149-153.
|
26. |
Villanueva V, Lopez FJ, Serratosa JM, et al. Control of seizures in different stages of partial epilepsy:LACO-EXP, a Spanish retrospective study of lacosamide. Epilepsy Behav, 2013, 29(2):349-356.
|
27. |
Wehner T, Bauer S, Hamer HM, et al. Six months of postmarketing experience with adjunctive lacosamide in patients with pharmacoresistant focal epilepsy at a tertiary epilepsy center in Germany. Epilepsy Behav, 2009, 16(3):423-425.
|
28. |
Garcia-Morales I, Delgado R T, Falip M, et al. Early clinical experience with lacosamide as adjunctive therapy in patients with refractory focal epilepsy and nocturnal seizures. Seizure, 2011, 20(10):801-804.
|
29. |
Verrotti A, Loiacono G, Pizzolorusso A, et al. Lacosamide in pediatric and adult patients:comparison of efficacy and safety. Seizure, 2013, 22(3):210-216.
|
30. |
Wechsler RT, Li G, French J, et al. Conversion to lacosamide monotherapy in the treatment of focal epilepsy:results from a historical-controlled, multicenter, double-blind study. Epilepsia, 2014, 55(7):1088-1098.
|
31. |
Wasterlain CG, Stohr T, Matagne A. The acute and chronic effects of the novel anticonvulsant lacosamide in an experimental model of status epilepticus. Epilepsy Res, 2011, 94(1-2):10-17.
|
32. |
Albers JM, Moddel G, Dittrich R, et al. Intravenous lacosamide——an effective add-on treatment of refractory status epilepticus. Seizure, 2011, 20(5):428-430.
|
33. |
Goodwin H, Hinson HE, Shermock KM, et al. The use of lacosamide in refractory status epilepticus. Neurocrit Care, 2011, 14(3):348-353.
|
34. |
Hofler J, Unterberger I, Dobesberger J, et al. Intravenous lacosamide in status epilepticus and seizure clusters. Epilepsia, 2011, 52(10):e148-152.
|
35. |
Kellinghaus C, Berning S, Immisch I, et al. Intravenous lacosamide for treatment of status epilepticus. Acta Neurol Scand, 2011, 123(2):137-141.
|
36. |
Cherry S, Judd L, Muniz JC, et al. Safety and efficacy of lacosamide in the intensive care unit. Neurocrit Care, 2012, 16(2):294-298.
|
37. |
Mnatsakanyan L, Chung JM, Tsimerinov EI, et al. Intravenous Lacosamide in refractory nonconvulsive status epilepticus. Seizure, 2012, 21(3):198-201.
|
38. |
Garces M, Villanueva V, Mauri JA, et al. Factors influencing response to intravenous lacosamide in emergency situations:LACO-IV study. Epilepsy Behav, 2014, 36(6):144-152.
|
39. |
Chinnasami S, Rathore C, Duncan JS. Sinus node dysfunction:an adverse effect of lacosamide. Epilepsia, 2013, 54(6):e90-93.
|
40. |
DeGiorgio AC, Desso E, Lee L, et al. Ventricular tachycardia associated with lacosamide co-medication in drug-resistant epilepsy. Epilepsy Behav Case Rep, 2012, 1(1):26-28.
|
41. |
Kaufman KR, Velez AE, Wong S, et al. Low-dose lacosamide-induced atrial fibrillation:Case analysis with literature review. Epilepsy Behav Case Rep, 2013, 1(1):22-25.
|